Immunocompetent PDMS‐Free Organ‐on‐Chip Model of Cervical Cancer Integrating Patient‐Specific Cervical Fibroblasts and Neutrophils

Author:

Kromidas Elena1,Geier Alicia1,Weghofer Adrian1,Liu Hui‐Yu1,Weiss Martin23,Loskill Peter124ORCID

Affiliation:

1. Department for Microphysiological Systems, Institute of Biomedical Engineering, Faculty of Medicine Eberhard Karls University Tübingen 72074 Tübingen Germany

2. Department for Biomedicine and Materials Science NMI Natural and Medical Sciences Institute at the University of Tübingen 72770 Reutlingen Germany

3. Department for Women's Health, Faculty of Medicine Eberhard Karls University Tübingen 72076 Tübingen Germany

4. 3R Center Tübingen for In Vitro Models and Alternatives to Animal Testing 72074 Tübingen Germany

Abstract

AbstractDespite preventive measures and available treatments, cervical cancer still ranks as the fourth most prevalent cancer among women worldwide and remains the leading cause of cancer death in women in many developing countries. To gain further insights into pathogenesis and to develop novel (immuno)therapies, more sophisticated human models recreating patient heterogeneities and including aspects of the tumor microenvironment are urgently required. A novel polydimethylsiloxane‐free microfluidic platform, designed specifically for the generation and ccultivation of cervical cancerous tissue, is introduced. The microscale open‐top tissue chambers of the cervical cancer‐on‐chip (CCoC) enable facile generation and long‐term cultivation of SiHa spheroids in co‐culture with donor‐derived cervical fibroblasts. The resulting 3D tissue emulates physiological architecture and allows dissection of distinct effects of the stromal tissue on cancer viability and growth. Treatment with cisplatin at clinically‐relevant routes of administration and dosing highlights the platform's applicability for drug testing. Moreover, the model is amenable for integration and recruitment of donor‐derived neutrophils from the microvasculature‐like channel into the tissue, all while retaining their ability to produce neutrophil extracellular traps. In the future, the immunocompetent CCoC featuring donor‐specific primary cells and tumor spheroids has the potential to contribute to the development of new (immuno)therapeutic options.

Funder

Bundesinstitut für Risikobewertung

Publisher

Wiley

Subject

Pharmaceutical Science,Biomedical Engineering,Biomaterials

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3